Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Retained Earnings (2016 - 2025)

Cardiff Oncology's Retained Earnings history spans 15 years, with the latest figure at -$430.0 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 1264894.12% year-over-year to -$430.0 million; the TTM value through Dec 2025 reached -$430.0 million, down 1264894.12%, while the annual FY2025 figure was -$430.0 million, 1264894.12% down from the prior year.
  • Retained Earnings for Q4 2025 was -$430.0 million at Cardiff Oncology, down from $50000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $50000.0 in Q3 2025 and bottomed at -$430.0 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$246.9 million (2021), against an average of -$192.8 million.
  • The largest YoY upside for Retained Earnings was 100.01% in 2025 against a maximum downside of 1264894.12% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$259.8 million in 2021, then soared by 99.85% to -$395000.0 in 2022, then crashed by 85859.75% to -$339.5 million in 2023, then skyrocketed by 100.01% to $34000.0 in 2024, then tumbled by 1264894.12% to -$430.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Retained Earnings are -$430.0 million (Q4 2025), $50000.0 (Q3 2025), and -$411.6 million (Q2 2025).